Diasorin in the spotlight; analysts forecast solid results for the third quarter
Organic sales growth of 7 per cent is expected, along with a 10 per cent increase in adjusted EBITDA, with a margin of 31.7 per cent, up 30 basis points year-on-year
Le ultime da Radiocor
Fincantieri: Folgiero, accelera profittabilita', carico lavoro per 72,6 miliardi
Fincantieri: alza guidance 2026 dopo conti 9 mesi nelle attese (RCO)
Nvidia: Huang rassegna dimissioni da ceo, Kress ricoprira' ruolo ad interim (RCO)
(Il Sole 24 Ore Radiocor) - Diasorin is in the spotlight on the Milan Stock Exchange ahead of its third-quarter results, due on 12 November. The immunodiagnostics company is up by around three points, whilst the FTSE MIB is up slightly. Analysts at Deutsche Bank forecast ‘solid results’, buoyed ‘by a more favourable basis for comparison across all three segments’. In particular, they estimate “organic sales growth of 7% in the third quarter and a 10% increase in adjusted EBITDA, with a margin of 31.7 per cent, up 30 basis points year-on-year”.
The Immunodiagnostics division ‘(+6 per cent organic growth) is expected to accelerate thanks to a more favourable year-on-year comparison, whilst QuantiFeron is expected to remain a key growth driver, with no apparent competitive pressure from Roche in the European market’. Growth is also forecast for the Molecular Diagnostics division (+9%), which ‘is expected to benefit from a more favourable basis for comparison, supported by the initial contributions from the recently launched Liaison Plex and Nes solutions. However, weak demand for respiratory infection tests is expected to remain a drag on growth.”
Equita also expects ‘solid results’, with organic revenue growth of +7.6 per cent to 308 million and an adjusted EBITDA margin of 32.1 per cent, against adjusted EBITDA of 99 million (+12.5 per cent). These results, according to experts, will be “accompanied by a positive outlook for the fourth quarter and the confirmation of guidance for 2026”. The fundamentals of the diagnostics/life sciences sector “are improving and, specifically, we believe that Diasorin will benefit from the growth of Liaison Nes and Plex over the coming years”, the analysts add, raising the target price to 90.0 euros per share and upgrading their recommendation to ‘Buy’.
At business unit level, Equita forecasts revenue growth of 9.9 per cent to 218 million in immunodiagnostics in the third quarter, whilst for the full year the division is expected to reach 863 million (+5.1 per cent), in line with the guidance provided by the company, which estimates mid-single-digit organic growth. As for the Molecular Diagnostics unit, Equita forecasts revenue of 49 million for the quarter (+14.1 per cent) and 213 million for the full year (+8.9 per cent), “a more conservative forecast compared to the 2026 guidance, which targets low double-digit organic growth. Finally, for the Licensed Technologies business unit, the experts estimate quarterly revenue of 42 million (+13.1 per cent) and annual revenue of 172 million, in line with the company’s targets, which aim for growth in the mid-to-high to high single-digit range.
